US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by VERAXA Biotech GmbH

News headline image
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
From VERAXA Biotech GmbH
Via GlobeNewswire
Tickers VRXA
News headline image
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
From VERAXA Biotech GmbH
Via GlobeNewswire
Tickers VRXA
News headline image
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
From VERAXA Biotech GmbH
Via GlobeNewswire
Tickers VRXA
News headline image
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
From VERAXA Biotech GmbH
Via GlobeNewswire
Tickers VRXA
News headline image
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
From VERAXA Biotech GmbH
Via GlobeNewswire
Tickers VRXA
News headline image
VERAXA Biotech to Debut as a Publicly Traded Company Pioneering Next-Generation Cancer Therapies on June 11, 2026
From VERAXA Biotech GmbH
Via GlobeNewswire
News headline image
VERAXA Biotech Strengthens Financial Position with $27.5 Million Principal Amount Senior Secured Note Financing and $50 Million Share Purchase Agreement
From VERAXA Biotech GmbH
Via GlobeNewswire
News headline image
VERAXA Biotech Shareholders Approve Merger and Issuance of New Shares to Voyager Acquisition Corp.
From VERAXA Biotech GmbH
Via GlobeNewswire
News headline image
VERAXA Biotech and Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
From VERAXA Biotech GmbH
Via GlobeNewswire
News headline image
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
From VERAXA Biotech GmbH
Via GlobeNewswire
News headline image
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
From VERAXA Biotech GmbH
Via GlobeNewswire